Table of contents
Volume 87, Issue 6
Published online 3 September 2002 (585-689)
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics |
Letters to the Editor |
Corrigendum
Clinical
Impact of deprivation and rural residence on treatment of colorectal and lung cancer FREE
N C Campbell, A M Elliott, L Sharp, L D Ritchie, J Cassidy and J Little
Br J Cancer 87: 585-590; doi:10.1038/sj.bjc.6600515
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma FREE
P Österlund, A Orpana, I Elomaa, H Repo and H Joensuu
Br J Cancer 87: 591-599; doi:10.1038/sj.bjc.6600520
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours FREE
R J Francis, S K Sharma, C Springer, A J Green, L D Hope-Stone, L Sena, J Martin, K L Adamson, A Robbins, L Gumbrell, D O'Malley, E Tsiompanou, H Shahbakhti, S Webley, D Hochhauser, A J Hilson, D Blakey and R H J Begent
Br J Cancer 87: 600-607; doi:10.1038/sj.bjc.6600517
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin FREE
N E Schoemaker, C van Kesteren, H Rosing, S Jansen, M Swart, J Lieverst, D Fraier, M Breda, C Pellizzoni, R Spinelli, M Grazia Porro, J H Beijnen, J H M Schellens and W W ten Bokkel Huinink
Br J Cancer 87: 608-614; doi:10.1038/sj.bjc.6600516
Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS FREE
N Bijker, J L Peterse, I S Fentiman, J-P Julien, A A M Hart, A Avril, L Cataliotti and E J T Rutgers
Br J Cancer 87: 615-620; doi:10.1038/sj.bjc.6600514
Molecular and Cellular Pathology
Increased aquaporin 1 water channel expression inhuman brain tumours FREE
S Saadoun, M C Papadopoulos, D C Davies, B A Bell and S Krishna
Br J Cancer 87: 621-623; doi:10.1038/sj.bjc.6600512
DNA topoisomerase I and II expression in drug resistantgerm cell tumours FREE
D M Berney, J Shamash, J Gaffney, S Jordan and R T D Oliver
Br J Cancer 87: 624-629; doi:10.1038/sj.bjc.6600472
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer FREE
J-L Boulay, G Mild, A Lowy, J Reuter, M Lagrange, L Terracciano, U Laffer, R Herrmann and C Rochlitz
Br J Cancer 87: 630-634; doi:10.1038/sj.bjc.6600511
Genetics and Genomics
Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters FREE
G Fritz, C Brachetti, F Bahlmann, M Schmidt and B Kaina
Br J Cancer 87: 635-644; doi:10.1038/sj.bjc.6600510
Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc FREE
E Roccato, C Miranda, V Ranzi, M Gishizki, M A Pierotti and A Greco
Br J Cancer 87: 645-653; doi:10.1038/sj.bjc.6600544
Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer FREE
A D Watters, Z Latif, A Forsyth, I Dunn, M A Underwood, K M Grigor and J M S Bartlett
Br J Cancer 87: 654-658; doi:10.1038/sj.bjc.6600531
Experimental Therapeutics
Secreted and tumour targeted human carboxylesterase for activation of irinotecan FREE
D Oosterhoff, H M Pinedo, I H van der Meulen, M de Graaf, T Sone, F A Kruyt, V W van Beusechem, H J Haisma and W R Gerritsen
Br J Cancer 87: 659-664; doi:10.1038/sj.bjc.6600519
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity FREE
A H van Hattum, I J Hoogsteen, H M M Schlüper, M Maliepaard, G L Scheffer, R J Scheper, G Kohlhagen, Y Pommier, H M Pinedo and E Boven
Br J Cancer 87: 665-672; doi:10.1038/sj.bjc.6600508
Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis FREE
V Kostourou, S P Robinson, J E Cartwright and G St J Whitley
Br J Cancer 87: 673-680; doi:10.1038/sj.bjc.6600518
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy FREE
C Martínez, E García-Martín, R M Pizarro, F J García-Gamito and J A G Agúndez
Br J Cancer 87: 681-686; doi:10.1038/sj.bjc.6600494
Letters to the Editor
Oestrogen receptor beta: how should we measure this? FREE
V Speirs, P J Carder and M R J Lansdown
Br J Cancer 87: 687; doi:10.1038/sj.bjc.6600534
Reply: Expression of oestrogen receptor beta proteins in human breast cancer biopsies FREE
P T K Saunders and W R Miller
Br J Cancer 87: 688-689; doi:10.1038/sj.bjc.6600535
Corrigendum
Heparanase is a prognostic indicator for postoperative survival in pancreatic carcinoma FREE
J Rohloff, J Zinke, K Schoppmeyer, A Tannapfel, H Witzigmann, J Mössner, C Wittekind and K Caca
Br J Cancer 87: 689; doi:10.1038/sj.bjc.6600504
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
